Willem Mulder joins Radboud University Medical Center

The department of Internal Medicine of the Radboudumc is extremely happy to announce that on January 1st, 2021 Prof. dr. Willem Mulder (1976) will be joining the department, together with some of his researchers. Mulder, who will hold a parttime appointment at Eindhoven University of Technology, will serve as the bridge between the Radboudumc and TU/e. 

After obtaining a master’s degree in chemistry from the Utrecht University and a Ph.D. in biomedical engineering from the Eindhoven University of Technology, Mulder was recruited to the Icahn School of Medicine at Mount Sinai (ISMMS) in New York in 2006. Mulder currently is a tenured professor in the Biomedical Engineering and Imaging Institute where he directs ISMMS’s Nanomedicine Program. This research program focuses on the development and translation of nanomedicine and immuno-imaging approaches for cancer, cardiovascular diseases and organ transplantation. Most notably, Mulder pioneered a disease treatment paradigm involving the regulation of innate immune responses using nanobiologic therapeutics. Mulder is the principal investigator of multiple National Institutes of Health grants.

In addition to his position at Mount Sinai, Mulder held a secondary professor appointment at the Amsterdam UMC from 2012 to 2018, and currently at the Eindhoven University of Technology (TU/e). In 2013, Mulder received a VIDI grant and in 2018 he was awarded a VICI grant, both from the Dutch Research Council (NWO, ZonMW). Mulder has published more than 165 scientific publications in top scientific journals, including Nature Nanotechnology, Nature Reviews Drug Discovery, Nature Biomedical Engineering, Science Translational Medicine, Cell, Immunity, etc. His H-index is 69 and his work has been cited nearly 14.000 times. Mulder is a scientific founder of Trained Therapeutix Discovery, a biotech startup that aims to treat today’s most detrimental diseases with novel nanobiologic therapeutics.

The research of the department of Internal Medicine is focused on inflammation and the immune system in various diseases. Mulder’s research will focus on therapeutically regulating and imaging the immune system with innovative nanotechnology approaches. In addition to the Radboudumc, he will have an appointment at TU/e’s department of biomedical engineering. This will enable an exciting opportunity for collaboration and integration of the strengths of both departments and institutes.

The immuno-oncology revolution and the current COVID-19 pandemic underscore the importance of translational immunology research and biomedical engineering. Radboudumc and TU/e are frontrunners in these respective fields. At Mount Sinai, Mulder built a unique translational research program that integrates nanotechnology, immunology, disease model and in vivo imaging to yield innovative immunotherapy strategies. By moving his research activities to the Netherlands, Mulder will serve as the bridge between the Radboudumc and TU/e. 

• Want to know more about these subjects? Click on the buttons below for more news.

  News homepage news & media